Natriuretic peptides BNP and NT-pro-BNP: Established laboratory markers in clinical practice or just perspectives?

Clinica Chimica Acta

Volumn 349, Issue 1-2, 2004, Pages 25-38

  Pfister, R ^a   Schneider, C A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acute coronary syndrome; BNP; Heart failure; Left ventricular dysfunction; Natriuretic peptides; NT pro BNP

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MARKER; NEUROHORMONE;

AMINO TERMINAL SEQUENCE; AUTOMATION; BIOASSAY; BLOOD ANALYSIS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DYSPNEA; FIRST AID; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNORADIOMETRIC ASSAY; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REVIEW; SCREENING;

CORONARY DISEASE; GENETIC MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS;

EID: 4744348806     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.06.018     Document Type: Review

References (71)

1. T. Sudoh, K. Kangawa, N. Minamino, and H. Matsuo A new natriuretic peptide in porcine brain Nature 332 1988 78 81
2. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L. Jessup, R.J. Noble, M. Packer, M.A. Silver, L.W. Stevenson, R.J Gibbons, E.M. Antman, J.S. Alpert, D.P. Faxon, V. Fuster, A.K. Jacobs, L.F. Hiratza, R.O. Russell, S.C. Smith Jr. American College of Cardiology/American Heart Association ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol. A 38 2001 2101 2113
3. W.J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure Eur. Heart J. 22 2001 1527 1560
4. P.J. Hunt, T.G. Yandle, M.G. Nicholls, A.M. Richards, and E.A. Espiner The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma Biochem. Biophys. Res. Commun. 214 1995 1175 1183
5. K. Maeda, T. Tsutamoto, A. Wada, T. Hisanaga, and M. Kinoshita Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction Am. Heart J. 135 1998 825 832
6. S.J. Holmes, E.A. Espiner, A.M, Richards, T.G. Yandle, and C. Frampton Renal, endocrine, and hemodynamic-effects of human brain natriuretic peptide in normal man J. Clin. Endocrinol. Metab. 76 1993 91 96
7. A. Hammerer-Lercher, E. Neubauer, S. Muller, O. Pachineger, B. Puschendorf, and J. Mair Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction Clin. Chim. Acta 310 2001 193 197
8. R. Kazanegra, V. Cheng, A. Garcia, P. Krishnaswamy, N. Gardetto, P. Clopton, and A. Maisel A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study J. Card. Fail. 7 2001 21 29
9. R. Pfister, M. Scholz, K. Wielckens, E. Erdmann, and CA. Schneider The rank of natriuretic peptides NT-pro-BNP and BNP for the estimation of left-ventricular volume and function Dtsch. Med. Wochenschr. 2002 2605 2609
10. K. Yamamoto, J.C. Burnett Jr., M. Jougasaki, R.A. Nishimura, K.R. Bailey, Y. Saito, K. Nakao, and M.M. Redfield Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy Hypertension 28 1996 988 994
11. E. Lubien, A. DeMaria, P. Krishnaswamy, P. Clopton, J. Koon, R. Kazanegra, N. Gardetto, E. Wanner, and A.S. Maisel Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings Circulation 105 2002 595 601
12. R.S. Vasan, E.J. Benjamin, M.G. Larson, E.P. Leip, T.J. Wang, P.W. Wilson, and D. Levy Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunctionãThe Framingham Heart study JAMA 288 2002 1252 1259
13. A.L. Gerbes, L. Dagnino, T. Nguyen, and M. Nemer Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues J. Clin. Endocrinol. Metab. 78 1994 1307 1311
14. M. McNairy, N. Gardetto, P. Clopton, A. Garcia, P. Krishnaswamy, R. Kazanegra, M. Ziegler, and A.S. Maisel Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide Am. Heart J. 143 2002 406 411
15. K.T. Jensen, J. Carstens, P. Ivarsen, and E.B. Pedersen A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases Scand. J. Clin. Lab. Invest. 57 1997 529 540
16. L.K. Morrison, A. Harrison, P. Krishnaswamy, R. Kazanegra, P. Clopton, and A. Maisel Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea J. Am. Coll. Cardiol. 39 2002 202 209
17. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, P.W. Wilson, and R.S. Vasan Impact of obesity on plasma natriuretic peptide levels Circulation 109 2004 594 600
18. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N. Engl. J. Med. 327 1992 685 691
19. M. Bay, V. Kirk, J. Parner, C. Hassager, H. Neilsen, K. Krogsgaard, J. Trawinski, S. Boesgaard, and J. Andersvile NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function Heart 89 2003 150 154
20. T.A. McDonagh, S.D. Robb, D.R. Murdoch, J.J. Morton, I. Ford, C.E. Morrison, H. Tunstall-Pedoe, J.J. McMurray, and H.J. Dargie Biochemical detection of left-ventricular systolic dysfunction Lancet 351 1998 9 13
21. O.W. Nielsen, T.A. McDonagh, S.D. Robb, and H.J. Dargie Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population J. Am. Coll. Cardiol. 41 2003 113 120
22. R. Latini, S. Masson, I. Anand, D. Judd, A.P. Maggioni, Y.T. Chiang, M. Bevilacqua, M. Salio, P. Cadano, P.H. Dunselman, N.J. Holwerda, G. Tognoni, J.N. Cohn Valsartan Heart Failure Trial Investigators Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) Circulation 106 2002 2454 2458
23. W.H. Tang, J.P. Girod, M.J. Lee, R.C. Starling, J.B. Young, F. Van Lente, and G.S. Francis Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure Circulation 108 2003 2964 2966
24. K. Bibbins-Domingo, M. Ansari, N.B. Schiller, B. Massie, and M.A. Whooley B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study Circulation 108 2003 2987 2992
25. M.R. Cowie, A.D. Struthers, D.A. Wood, A.J. Coats, S.G. Thompson, P.A. Poole-Wilson, and G.C. Sutton Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care Lancet 350 1997 1349 1353
26. S.P. Wright, R.N. Doughty, A. Pearl, G.D. Gamble, G.A. Whalley, H.J. Walsh, G. Gordon, W. Bagg, H. Oxenham, T. Yandle, M. Richards, and N. Sharpe Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary careãa randomized, controlled trial J. Am. Coll. Cardiol. 42 2003 1793 1800
27. M. Davis, E. Espiner, G. Richards, J. Billings, I. Town, A. Neill, C. Drennan, M. Richards, J. Turner, and T. Yandle Plasma brain natriuretic peptide in assessment of acute dyspnoea Lancet 343 1994 440 444
28. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, T. Omland, A.B. Storrow, W.T. Abraham, A.H. Wu, P. Clopton, P.G. Steg, A. Westheim, C.W. Knudsen, A. Perez, R. Kazanegra, H.C. Hermann, P.A. McCullough Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N. Engl. J. Med. 347 2002 161 167
29. S.J. Jacobsen, E.J. Bergstralh, H.A. Guess, S.K. Katusic, G.G. Klee, J.E. Oesterling, and M.M. Lieber Predictive properties of serum-prostate-specific antigen testing in a community-based setting Arch. Intern. Med. 156 1996 2462 2468
30. P.A. McCullough, R.M. Nowak, J. McCord, J.E. Hollander, H.C. Herrmann, P.G. Steg, P. Duc, A. Westheim, T. Omland, C.W. Knudsen, A.B. Storrow, W.T. Abraham, S. Lamba, A.H. Wu, A. Perez, P. Clopton, P. Krishnaswamy, R. Kazanegra, and A.S. Maisel B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study Circulation 106 2002 416 422
31. A.S. Maisel The diagnosis of acute congestive heart failure: role of BNP measurements Heart Fail. Rev. 8 2003 327 334
32. R. Fathi, N. Isbel, B. Haluska, C. Case, D.W. Johnson, and T.H. Marwick Correlates of subclinical left ventricular dysfunction in ESRD Am. J. Kidney Dis. 41 2003 1016 1025
33. S.K. James, B. Lindahl, A. Siegbahn, M. Stridsberg, P. Venge, P. Armstrong, E.S. Barnathan, R. Califf, E.J. Topol, M.L. Simoons, and L. Wallentin N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery diseaseãA Global Utilization of Strategies to Open occluded arteries (GUSTO)-IV substudy Circulation 108 2003 275 281
34. P.A. McCullough, P. Duc, T. Omland, J. McCord, R.M. Nowak, J.E. Hollander, H.C. Herrmann, P.G. Steg, A. Westheim, C.W. Knudsen, A.B. Storrow, W.T. Abraham, S. Lamba, A.H. Wu, A. Perez, P. Clopton, P. Krishnaswamy, R. Kazanegra, A.S. Maisel Breathing Not Properly Multinational Study Investigators B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study Am. J. Kidney Dis. 41 2003 571 579
35. C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, M. Pfisterer, and A.P. Perruchoud Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea N. Engl. J. Med. 350 2004 647 654
36. A. Bayes-Genis, M. Santalo-Bel, E. Zapico-Muniz, L. Lopez, C. Cotes, J. Bellido, R. Leta, P. Casan, and J. Ordonez-Llanos N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction Eur. J. Heart Fail. 6 2004 301 308
37. J.G. Lainchbury, E. Campbell, C.M. Frampton, T.G. Yandle, M.G. Nicholls, and A.M. Richards Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath J. Am. Coll. Cardiol. 42 2003 728 735
38. J. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. vonScheidt Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J. Am. Coll. Cardiol. 38 2001 1934 1941
39. A. Harrison, L.K. Morrison, P. Krishnaswamy, R. Kazanegra, P. Clopton, Q. Dao, P. Hlavin, and A.S. Maisel B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea Ann. Emerg. Med. 39 2002 131 138
40. T.A. McDonagh, A.D. Cunningham, C.E. Morrison, J.J. McMurray, I. Ford, J.J. Morton, and H.J. Dargie Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart 86 2001 21 26
41. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, T. Omland, P.A. Wolf, and R.S. Vasan Plasma natriuretic peptide levels and the risk of cardiovascular events and death N. Engl. J. Med. 350 2004 655 663
42. R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, and R. Pacher B-type natriuretic peptide predicts sudden death in patients with chronic heart failure Circulation 105 2002 2392 2397
43. A.M. Richards, R. Doughty, M.G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E.A. Espiner, C. Frampton, and T.G. Yandle Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group Circulation 99 1999 786 792
44. K. Kawai, K. Hata, H. Takaoka, H. Kawai, and M. Yokoyama Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment Am. Heart J. 141 2001 925 932
45. V. Cheng, R. Kazanagra, A. Garcia, L. Lenert, P. Krihnaswamy, N. Gardetto, P. Clopton, and A. Maisel A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study J. Am. Coll. Cardiol. 37 2001 386 391
46. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
47. A.M. Richards, R. Doughty, M.G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E.A. Espiner, C. Frampton, and T.G. Yandle Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group Circulation 99 1999 786 792
48. S. Talwar, I.B. Squire, P.F. Downie, A.M. Mccullough, M.C. Campton, J.E. Davies, D.B. Barnett, and L.L. Ng Profile of plasma N-terminal proBNP following acute myocardial infarction-correlation with left ventricular systolic dysfunction Eur. Heart J. 21 2000 1514 1521
49. J. Tateishi, M. Masutani, M. Ohyanagi, and T. Iwasaki Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty Clin. Cardiol. 23 2000 776 780
50. K. Marumoto, M. Hamada, and K. Hiwada Increased secretion of atrial and brain natriuretic peptides during acute myocardial-ischemia induced by dynamic exercise in patients with angina-pectoris Clin. Sci. 88 1995 551 556
51. A.M. Richards, M.G. Nicholls, T.G. Yandle, C. Frampton, E.A. Espiner, J.G. Turner, R.C. Buttimore, J.G. Laichbury, J.M. Elliot, H. Ikram, I.G. Crozier, and D.W. Smyth Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction Circulation 97 1998 1921 1929
52. J.A. de Lemos, D.A. Morrow, J.H. Bentley, T. Omland, M.S. Sabatine, C.H. McCabe, C. Hall, C.P. Cannon, E. Braunwald The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N. Engl. J. Med. 345 2001 1014 1021
53. T. Omland, A. Persson, and L. Ng N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes Circulation 106 2002 2913 2918
54. T. Jernberg, M. Stridsberg, P. Venge, and B. Lindahl N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation J. Am. Coll. Cardiol. 40 2002 437 445
55. A.M. Richards, M.G. Nicholls, E.A. Espiner, J.G. Lainchbury, R.W. Troughton, J. Elliot, C. Frampton, J. Turner, I.G. Crozier, and T.G. Yandle B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction Circulation 107 2003 2786 2792
56. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18 J. Am. Coll. Cardiol. 41 2003 1264 1272
57. T. Jernberg, B. Lindahl, A. Siegbahn, B. Andren, G. Frostfeldt, B. Lagerqvist, M. Stridsberg, P. Venge, and L. Wallentin N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease J. Am. Coll. Cardiol. 42 3 2003 1909 1916
58. N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki, M. Kakishita, K. Fukushima, Y. Okano, N. Nakashini, K. Miyatake, and K. Kangawa Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865 870
59. N. Kucher, and S.Z. Goldhaber Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism Circulation 108 2003 2191 2194
60. N. Kucher, G. Printzen, and S.Z. Goldhaber Prognostic role of brain natriuretic peptide in acute pulmonary embolism Circulation 107 2003 2545 2547
61. S. Kruger, J. Graf, and M.W. Merx Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism Am. Heart J. 147 2004 60 65
62. M.H. Park, R.L. Scott, P.A. Uber, B.C. Harris, R. Chambers, and M.R. Mehra Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function Am. J. Cardiol. 90 2002 1326 1329
63. R.G. Masters, R.A. Davies, J.P. Veinot, P.J. Hendry, S.J. Smith, A.J. de Bold Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans Circulation 100 1999 287 291
64. I. Hervas, L. Almenar, J.L. Perez-Pastor, M. Chirivella, A. Osa, L. Martinez-Dolz, P. Bello, J.F. Marti, M.A. Arnau, F. Vera, J. Rueda, M. Palencia, and A. Mateo Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection Nucl. Med. Commun. 24 2003 925 931
65. K.T. Yeo, A.H. Wu, F.S. Apple, M.H. Kroll, R.H. Christenson, K.B. Lewandrowski, F.A. Sedor, and A.W. Butch Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay Clin. Chim. Acta 338 2003 107 115
66. A. Clerico, R. Caprioli, S. Del Ry, and D. Giannessi Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis J. Endocrinol. Invest. 24 2001 24 30
67. A. Cataliotti, L.S. Malatino, M. Jougasaki, C. Zoccali, P. Castellino, G. Giacone, I. Bellanouva, R. Tripepi, G. Seminara, S. Parlongo, B. Stancanelli, G. Bonanno, P. Fatuzzo, F. Rapisadra, P. Belluardo, S.S. Signorelli, D.M. Heublin, J.G. Lainchbury, H.K. Leskinen, K.R. Bailey, M.M. Redfield, J.C. Burnett Jr. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling Mayo Clin. Proc. 76 2001 1111 1119
68. A.H. Wu, A. Smith, S. Wieczorek, J.F. Mather, B. Duncan, C.M. White, C. McGill, D. Katten, and G. Heller Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure Am. J. Cardiol. 92 2003 628 631
69. R. Pfister, M. Scholz, K. Wielckens, E. Erdmann, and C.A. Schneider Use of NT-proBNP in routine testing and comparison to BNP Eur. J. Heart Fail. 6 2004 289 293
70. T. Mueller, A. Gegenhuber, W. Poelz, and M. Haltmayer Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease Clin. Chim. Acta 341 2004 41 48
71. S.J. Wieczorek, A.H. Wu, R. Christenson, P. Krishnaswamy, S. Gottlieb, T. Rosano, D. Hager, N. Gardetto, A. Chiu, K.R. Bailly, and A. Maisel A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation Am. Heart J. 144 2002 834 839